ArticlePeerJ2021
The characteristics and roles of antimicrobial peptides as potential treatment for antibiotic-resistant pathogens: a review.
Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Beyond proteolysis: rational modification of mucin-derived peptidomimetics with enhanced metal-mediated antimicrobial activity.RSC advances · 2026Article
- Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Hostile Environments: Modifying Surfaces to Block Microbial Adhesion and Biofilm Formation.Biomolecules · 2025Review
- In Vivo Antimicrobial Activity of Nisin Z AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Advances in Antimicrobial Peptides: Mechanisms, Design Innovations, and Biomedical Potential.Molecules (Basel, Switzerland) · 2025Review
- Computational analysis of antimicrobial peptides targeting key receptors in infection-related cardiovascular diseases: molecular docking and dynamics insights.Scientific reports · 2025Article
- A study on antimicrobial activity of lysine-like peptoids for the development of new antimicrobials.Archives of microbiology · 2025Article
- Unlocking the power of antimicrobial peptides: advances in production, optimization, and therapeutics.Frontiers in cellular and infection microbiology · 2025Review
- Accelerating antimicrobial peptide design: Leveraging deep learning for rapid discovery.PloS one · 2024Article
- Avidumicin, a novel cyclic bacteriocin, produced by Cutibacterium avidum shows anti-Cutibacterium acnes activity.The Journal of antibiotics · 2023Article
- Repurposing HDAC inhibitors to enhance ribonuclease 4 and 7 expression and reduce urinary tract infection.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Anti-methicillin-resistantPeerJ · 2023Article
- 10-mer and 9-mer WALK Peptides with Both Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial Peptides-Mechanisms of Action, Antimicrobial Effects and Clinical Applications.Antibiotics (Basel, Switzerland) · 2022Review
- Overcoming Methicillin-ResistanceAntibiotics (Basel, Switzerland) · 2022Review
- Old and modern antibiotic structures with potential for today's infections.ADMET & DMPK · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of antibiotic-resistant bacteria has become a significant and ever-increasing threat to global public health, increasing both morbidity and mortality rates, and the financial burden on health services. Infection by drug-resistant bacteria is anticipated to contribute to the demise of almost 10 million people by the year 2050 unless a competent and effective response is devised to engage with this issue. The emergence and spread of resistance are commonly caused by the excessive or inappropriate use of antibiotics and substandard pharmaceuticals. It arises when pathogens adapt to different conditions and develop self-defence mechanisms. Currently, novel antimicrobial peptides (AMPs) have been reported to be the sole cure for some clinical cases of infectious diseases such as sepsis and skin infections, although these agents may, on occasion, require administration together with an adjunctive low-dose antibiotic. Although AMPs are a promising alternative form of anti-microbial therapy and easily applied in the medical sector, they still have limitations that should not be taken lightly. Hence, this review explores the characteristics, advantages and disadvantages of AMPs for their potential in treating antibiotic-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.